All In Biotech

Drug Trial Radar · NCT06261814

Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

2D and 3D Contrast Enhanced Ultrasound of Chemoembolization

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

266

Planned (sponsor's estimate)

Start

Aug 7, 2024

Primary completion

Jul 1, 2027

Study completion Jan 1, 2028

Sponsor

Lead sponsor
john eisenbreyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Feb 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.

Conditions

  • Liver Neoplasms

Interventions

  • Sulfur Hexafluoride Lipid MicrospheresDrug

    Given IV

  • Contrast-Enhanced UltrasoundProcedure

    Undergo CEUS

  • Transarterial ChemoembolizationProcedure

    Undergo TACE

  • Medical Chart ReviewOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RecurrenceTime frame: Up to 6 months
  2. SensitivityTime frame: Up to 6 months
  3. SpecificityTime frame: Up to 6 months
  4. Positive predictive valueTime frame: Up to 6 months
  5. Negative predictive valueTime frame: Up to 6 months
  6. False discovery rateTime frame: Up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.